{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:09:41Z","timestamp":1790838581589,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["lrjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.leukres.2014.09.016","type":"journal-article","created":{"date-parts":[[2014,10,5]],"date-time":"2014-10-05T20:25:16Z","timestamp":1412540716000},"page":"1392-1398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["How tyrosine kinase inhibitors impair metabolism and endocrine system function: A systematic updated review"],"prefix":"10.1016","volume":"38","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Molica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2014.09.016_bib0005","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia \u2013 advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2014.09.016_bib0010","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1280","article-title":"Regulation of the c-Abl and Bcr-Abl tyrosine kinases","volume":"5","author":"Hantschel","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.leukres.2014.09.016_bib0015","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenous leukemia: biology and therapy","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.leukres.2014.09.016_bib0020","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.hoc.2004.03.008","article-title":"Biology of chronic myelogenous leukemia-signaling pathways of initiation and transformation","volume":"18","author":"Melo","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.leukres.2014.09.016_bib0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/shem.2003.50034","article-title":"Molecular mechanisms of transformation by the BCR-ABL oncogene","volume":"40","author":"Sattler","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2014.09.016_bib0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1615\/CritRevOncog.v17.i1.30","article-title":"Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukemia","volume":"17","author":"Yeung","year":"2012","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.leukres.2014.09.016_bib0035","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukaemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.09.016_bib0040","volume":"112","author":"O\u2019Brien","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.09.016_bib0045","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.09.016_bib0050","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","volume":"95","author":"Shah","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2014.09.016_bib0055","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.09.016_bib0060","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.09.016_bib0065","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1182\/blood.V120.21.1676.1676","article-title":"ENESTnd 4-year update: continued superiority of nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP)","volume":"120","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.09.016_bib0070","first-page":"1","article-title":"a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia","volume":"30","author":"Hill","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.leukres.2014.09.016_bib0075","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s40265-014-0216-6","article-title":"Ponatinib: a review of its use in adults with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"74","author":"Hoy","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.leukres.2014.09.016_bib0080","doi-asserted-by":"crossref","first-page":"37747","DOI":"10.1074\/jbc.M105796200","article-title":"(STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells","volume":"276","author":"Boren","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2014.09.016_bib0085","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.1158\/1078-0432.CCR-04-0039","article-title":"Imatinib (STI571) mediated changes in glucose metabolism in human leukemia BCR-ABL positive cells","volume":"10","author":"Gottschalk","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2014.09.016_bib0090","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1038\/sj.onc.1208461","article-title":"Chronic myeloid leukaemia: an investigation into the role of BCR-ABL induced abnormalities in glucose transport regulation","volume":"24","author":"Barnes","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2014.09.016_bib0095","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00129785-200505050-00002","article-title":"Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications","volume":"5","author":"Serkova","year":"2005","journal-title":"Am J Pharmacogenomics"},{"key":"10.1016\/j.leukres.2014.09.016_bib0100","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1158\/1078-0432.CCR-08-3291","article-title":"Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells","volume":"15","author":"Kominsky","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2014.09.016_bib0105","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1476-5381.2009.00345.x","volume":"158","author":"Klawitter","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.leukres.2014.09.016_bib0110","doi-asserted-by":"crossref","first-page":"e21924","DOI":"10.1371\/journal.pone.0021924","article-title":"Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells","volume":"6","author":"Kluza","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.leukres.2014.09.016_bib0115","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1200\/JCO.2004.04.217","article-title":"Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukaemia patients responsive to treatment","volume":"22","author":"Breccia","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.09.016_bib0120","first-page":"ECR21","article-title":"Reduction of glycosilated hemoglobin with stable insulin levels in a diabetic patient with chronic myeloid leukaemia responsive to imatinib","volume":"90","author":"Breccia","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2014.09.016_bib0125","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1056\/NEJM200503103521023","article-title":"Imatinib and regression of type 2 diabetes","volume":"352","author":"Veneri","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2014.09.016_bib0130","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4158\/EP.13.2.126","article-title":"Imatinib and type 2 diabetes","volume":"13","author":"Dingli","year":"2007","journal-title":"Endocr Pract"},{"key":"10.1016\/j.leukres.2014.09.016_bib0135","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.leukres.2009.08.003","article-title":"Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia","volume":"34","author":"Mariani","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2014.09.016_bib0140","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/j.leukres.2009.11.021","article-title":"Modifications of fasting glucose values as first sign of resistance in chronic myeloid leukemia chronic phase patients during imatinib treatment","volume":"34","author":"Breccia","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2014.09.016_bib0145","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1096\/fj.06-6910com","article-title":"Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and antiapoptotic preconditioning","volume":"21","author":"Hagerkvist","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.leukres.2014.09.016_bib0150","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1042\/CS20070122","article-title":"Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet","volume":"114","author":"Hagerkvist","year":"2008","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.leukres.2014.09.016_bib0155","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1210\/jc.2010-0086","article-title":"Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?","volume":"95","author":"Fitter","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.leukres.2014.09.016_bib0160","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/JME-12-0003","article-title":"Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion","volume":"48","author":"Fitter","year":"2012","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.leukres.2014.09.016_bib0165","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.leukres.2007.01.024","article-title":"Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib","volume":"31","author":"Breccia","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2014.09.016_bib0170","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1182\/blood.V110.11.4588.4588","article-title":"Analysis of glucose profiles in imatinib-resistant or intolerant chronic myelogenous leukemia (CML) patients treated with nilotinib: lack of correlation between glucose levels and nilotinib efficacy","volume":"110","author":"le Coutre","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.09.016_bib0175","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cncr.26249","article-title":"Expanding Nilotinib access in clinical trials (ENACT): an open-label multicentre study of oral nilotinib in adult patients with imatinib-intolerant Philadelphia chromosome-positive leukemia in the chronic phase","volume":"1118","author":"Nicolini","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2014.09.016_bib0180","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1016\/j.leukres.2011.12.011","article-title":"Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index","volume":"36","author":"Breccia","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2014.09.016_bib0185","first-page":"116","article-title":"Efficacy and safety of nilotinib in chronic phase (CP) chronic myeloid leukemia (CML) patients (pts) with type 2 diabetes in the ENESTnd trial","author":"Saglio","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.09.016_bib0190","first-page":"120","article-title":"Incidence of hyperglycemia by 3 years in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib or imatinib in ENESTnd","author":"Rea","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.09.016_bib0195","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.3324\/haematol.2013.086355","article-title":"Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia","volume":"98","author":"Racil","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2014.09.016_bib0200","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1078155210378913","article-title":"Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice","volume":"17","author":"Agostino","year":"2010","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.leukres.2014.09.016_bib0205","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.leukres.2008.01.015","article-title":"Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib","volume":"32","author":"Breccia","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2014.09.016_bib0210","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2014.09.016_bib0215","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1161\/01.ATV.0000128321.91782.b9","article-title":"Protective role of imatinib in atherosclerosis","volume":"24","author":"Kadowaki","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.leukres.2014.09.016_bib0220","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/01.ATV.0000124105.39900.db","article-title":"Imatinib attenuates diabetes-associated atherosclerosis","volume":"24","author":"Lassila","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.leukres.2014.09.016_bib0225","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1161\/01.CIR.0000117234.08626.7C","article-title":"Oral imatinib mesylate (STI571\/gleevec) improves the efficacy of local intravascular endothelial growth factor-C gene transfer in reducing neointimal growth in hypercholesterolemic rabbits","volume":"109","author":"Leppanen","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.leukres.2014.09.016_bib0230","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10456-007-9080-2","article-title":"Anti-angiogenic effects of imatinib target smooth muscle cells but not endothelial cells","volume":"10","author":"Rocha","year":"2007","journal-title":"Angiogenesis"},{"key":"10.1016\/j.leukres.2014.09.016_bib0235","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1056\/NEJMc052500","article-title":"Imatinib and hyperlipidemia","volume":"353","author":"Gottardi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2014.09.016_bib0240","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3324\/haematol.11680","article-title":"Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib","volume":"93","author":"Franceschino","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2014.09.016_bib0245","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.leukres.2009.02.024","article-title":"Hypolipemiant besides antileukemic effect of imatinib mesylate","volume":"33","author":"Gologan","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2014.09.016_bib0250","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.09.016_bib0255","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1182\/blood.V122.21.1503.1503","article-title":"Hypercholesterolemia in imatinib intolerant\/resistant CML-CP patients treated with nilotinib: a retrospective analysis","volume":"122","author":"Hiwase","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.09.016_bib0260","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1182\/blood.V122.21.4042.4042","article-title":"Prospective analysis of plasma cholesterol and triglycerides in patients with chronic phase-chronic myeloid leukemia during treatment with the 2nd generation tyrosine kinase inhibitor nilotinib","volume":"122","author":"Rea","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.09.016_bib0265","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia","volume":"17","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2014.09.016_bib0270","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3324\/haematol.2014.104075","article-title":"Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase\u2013chronic myeloid leukemia","volume":"99","author":"Rea","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2014.09.016_bib0280","first-page":"679","article-title":"EPIC: a phase 3 trial of ponatinib vs imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CP-CML)","volume":"99","author":"Chauh","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2014.09.016_bib0285","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bone.2011.04.014","article-title":"The skeletal effects of the tyrosine kinase inhibitor nilotinib","volume":"49","author":"O'Sullivan","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.leukres.2014.09.016_bib0290","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1182\/blood-2005-09-3568","article-title":"Imatinib as a potential antiresorptive therapy for bone disease","volume":"107","author":"Dewar","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.09.016_bib0295","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2006.09.007","article-title":"Imatinib Mesylate (Gleevec) enhances mature osteoclast apopstosis and suppresses osteoclast bone resorbing activity","volume":"55","author":"El Hajj Dib","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.leukres.2014.09.016_bib0300","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1182\/blood-2007-07-104281","article-title":"Long-term imatinib therapy promotes bone formation in CML patients","volume":"111","author":"Fitter","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.09.016_bib0305","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.leukres.2013.02.005","article-title":"Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors","volume":"37","author":"Berman","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2014.09.016_bib0310","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/ajh.20778","article-title":"Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukaemia in late chronic phase, and this effects is associated with response","volume":"82","author":"Osorio","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2014.09.016_bib0315","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1056\/NEJMc062388","article-title":"Imatinib mesylate, increased bone formation and secondary hyperparathyroidism","volume":"355","author":"Grey","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2014.09.016_bib0320","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood-2009-08-237404","article-title":"Dysregulation of bone remodeling by imatinib mesylate","volume":"115","author":"Vandyke","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.09.016_bib0325","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/ajh.23113","article-title":"Imatinib mesylate induces massive and non-specific aminoaciduria in CML patients","volume":"87","author":"Ianotto","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2014.09.016_bib0330","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ajh.23155","article-title":"Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib","volume":"87","author":"Jonsson","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2014.09.016_bib0335","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1210\/jc.2012-2426","article-title":"Prospective histomorphometric and DXA evaluation of bone remodelling in imatinib-treated CML patients: evidence for site-specific skeletal effects","volume":"98","author":"Vandyke","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.leukres.2014.09.016_bib0340","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hon.988","article-title":"Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors","volume":"30","author":"Tibullo","year":"2012","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.leukres.2014.09.016_bib0350","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/jbmr.85","article-title":"The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo","volume":"25","author":"Vandyke","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.leukres.2014.09.016_bib0355","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/leu.2010.84","article-title":"Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro","volume":"24","author":"Jonsson","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.09.016_bib0360","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-12-0400","article-title":"Effects of tyrosine kinase inhibitors on bone metabolism","author":"Aleman","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.leukres.2014.09.016_bib0365","doi-asserted-by":"crossref","first-page":"e34914","DOI":"10.1371\/journal.pone.0034914","article-title":"Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects","volume":"7","author":"Garcia-Gomez","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.leukres.2014.09.016_bib0370","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1742-1241.2008.01856.x","article-title":"Is there any relationship between imatinib mesylate medication and hypothalamic\u2013pituitary\u2013adrenal axis dysfunction?","volume":"64","author":"Bilgir","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.leukres.2014.09.016_bib0375","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1089\/thy.2010.0251","article-title":"Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia","volume":"20","author":"Kim","year":"2010","journal-title":"Thyroid"},{"key":"10.1016\/j.leukres.2014.09.016_bib0380","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1530\/EJE-08-0648","article-title":"Tyrosine kinase inhibitors and modifications of thyroid function tests: a review","volume":"160","author":"Illouz","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.leukres.2014.09.016_bib0385","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.leukres.2011.11.003","article-title":"Imatinib does not impair gonadal function","volume":"36","author":"Chuah","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2014.09.016_bib0390","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.leukres.2011.09.025","article-title":"Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukemic mouse model","volume":"36","author":"Schultheis","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2014.09.016_bib0395","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1634\/theoncologist.2011-0137","article-title":"Will imatinib compromise reproductive capacity?","volume":"16","author":"Zamah","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.leukres.2014.09.016_bib0400","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1200\/JCO.2005.04.6557","article-title":"Pregnancy among patients with chronic myeloid treated with imatinib","volume":"24","author":"Ault","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.09.016_bib0405","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.09.016_bib0410","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/S0140-6736(03)13554-4","article-title":"Gynaecomastia in men with chronic myeloid leukemia after imatinib","volume":"361","author":"Gambacorti-Passerini","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2014.09.016_bib0415","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/leu.2008.106","article-title":"Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia","volume":"22","author":"Caocci","year":"2008","journal-title":"Leukemia"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614002987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614002987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T01:36:56Z","timestamp":1650332216000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212614002987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":81,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0145212614002987"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2014.09.016","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How tyrosine kinase inhibitors impair metabolism and endocrine system function: A systematic updated review","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2014.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}